The 2022 offering of Training in Neurotherapeutics Discovery and Development for Academic Scientists will be held Monday, March 28 to Thursday, March 31, 2022 at the UC Davis Conference Center in Davis, California.
The deadline for applications is January 24, 2022. Successful applicants will receive free tuition and all travel expenses are reimbursed. If you are are an academic researcher seeking to conduct non-clinical neurotherapeutics discovery and development, you are encouraged to apply. The course does not provide training in clinical trials.
Course Topics
Some of the topics to be covered in the course include:
- Overview of the Neurotherapeutics Discovery and Development Process
- Generating Lead Compounds (Target and Pathway Identification, Biology Basics for Identifying Hits, Medicinal Chemistry, Moving from Hit to Lead to Clinical Candidate, Alternative Approaches to Lead Generation
- ADME, Formulation and Non-Clinical Proof-of-Concept
- Preclinical Proof-of-Concept/Target Engagement Studies
- Principles of Biological Therapies and the Discovery and Development of Specific Biological Therapies for Neuroscience, Including Antibody-Based Therapies, Cell-Based Therapies, and Gene-Based Therapies
- Toxicology, IND Enabling Studies, Preparation of the IND
- Interacting with the FDA
- Intellectual Property
- Funding Academic Drug Discovery Research
Eligibility
This course is designed for advanced post-doctoral researchers and faculty members who are engaged, or would like to become engaged, in neurotherapeutics discovery and development. Occasionally advanced graduate students are accepted. Senior academic professionals are particularly invited to apply if they are considering a career transition to drug discovery and development. Applicants will generally have a doctoral degree in a relevant subject area (Ph.D., M.D., M.D./Ph.D., D.O., D.V.M., Pharm.D. or equivalent). Students interested in applying should contact the course organizers to request a determination of eligibility. NIH policy provides that research education programs should be used primarily for the education of U.S. citizens and permanent residents. Individuals primarily employed in industry are not eligible for this training program.
Individuals from racial and ethnic groups underrepresented in biomedical research, individuals with disabilities and women are particularly encouraged to apply.